Four reasons to question “new generation” monoclonal antibody Alzheimer’s drugs such as aducanumab (Aduhelm), lecanemab (Leqembi), donanemab

By SharpBrains | September 25, 2023

New Alzheimer’s Drugs Don’t Deserve the Hype (Being Patient): A promi­nent child­hood mem­o­ry is of my grand­par­ents liv­ing with and then dying from demen­tia. As is uni­ver­sal with demen­tia, there was a dou­ble blow: watch­ing my grand­par­ents lose their iden­ti­ty and see­ing the suf­fer­ing of those clos­est to them.

Read More

Brain Training @ BBC/ Nature: Fact, Hope, Hype?

By Alvaro Fernandez | April 19, 2010 |

Update (04/20/10): after read­ing the full BBC study in Nature, I wrote the arti­cle titled BBC “Brain Train­ing” Exper­i­ment: the Good, the Bad, the Ugly, say­ing that “you prob­a­bly saw the hun­dreds of media arti­cles titled “brain train­ing doesn’t work”, based on a BBC exper­i­ment. Once more, claims seem to go beyond the sci­ence backing…

Read More